



What effect do mycotoxins, cell wall components, enzymes and other mold components and metabolites have on our health?

Julia Hurraß · Rabea Teubel · Guido Fischer · Birger Heinzow · Gerhard A. Wiesmüller

Accepted: 23 April 2024 / Published online: 7 May 2024
 © The Author(s) 2024

Abstract The AWMF (Association of the Scientific Medical Societies) mold guideline “Medical clinical diagnostics for indoor mold exposure”—Update 2023 [44] concludes that there is limited or presumed evidence of a link between indoor dampness/mold exposure and health problems. However, there is inadequate or insufficient evidence for an association between indoor dampness/mold exposure and the environmental medical syndromes sick building syndrome (SBS), multiple chemical sensitivity (MCS) and chronic fatigue syndrome (CFS). Newly coined terms, such as biotoxiosis and mold and vapor hypersensitivity syndrome (MDHS) or volatotoxins, suggest a nosological specificity of a pathophysiological connection for which, however, there is no evidence to date. The background to this assessment is presented in this paper.

Birger Heinzow: *Formerly:* State Agency for Social Services (LAsD) Schleswig-Holstein, Kiel, Germany

Dr. rer. nat. J. Hurraß
 Department of Infection and Environmental Hygiene,
 Cologne Health Department, Cologne, Germany

R. Teubel · Prof. Dr. med. G. A. Wiesmüller (✉)
 Institute for Occupational, Social and Environmental
 Medicine, University Hospital RWTH Aachen, Aachen,
 Germany
ga.wiesmueller@post.rwth-aachen.de

Dr. rer. nat. G. Fischer
 Baden-Württemberg State Health Office in the Stuttgart
 Regional Council, Stuttgart, Germany

Dr. med. B. Heinzow
 Formerly: State Agency for Social Services (LAsD)
 Schleswig-Holstein, Kiel, Germany

Prof. Dr. med. G. A. Wiesmüller
 Laboratory Dr. Wisplinghoff, Cologne, Germany
 ZfMK—Center for Environment, Hygiene and Mycology
 Cologne, Cologne, Germany

Abbreviations

BRI	Building Related Illness
CFS	Chronic Fatigue Syndrome
DHS	Dermatophytes, yeasts, molds
IEI	Idiopathic Environmental Intolerance
LPS	Lipopolysaccharides
MCS	Multiple Chemical Sensitivity
MDHS	Mold and Dampness Hypersensitivity Syndrome
MVOC	Microbial volatile organic compounds
SBS	Sick Building Syndrome

Introduction

Disorders of well-being play a significant role in environmentally associated health disorders in general [12, 14] as well as in indoor-associated health disorders in particular [12–14]. Environmentally associated health disorders can be presented as environmental medical syndromes (group of similar disease symptoms, similar phenotype) [125]. Environmental medical syndromes include sick building syndrome (SBS), multiple chemical sensitivity (MCS) and chronic fatigue syndrome (CFS) [126]. A possible connection to indoor dampness/mold damage is discussed for both mood disorders and environmental medical syndromes [44]. There is more or less strong evidence for such a connection. The reasons for this are described in more detail below.

Molds, mycotoxins, cell wall components, enzymes and other mold components and metabolites

In taxonomy, fungi used to be subsumed under plants, but today they represent their own kingdom as fungi.

Fungi belong to the eukaryotes and have cell walls made of chitin and other glucans, whereas the cell walls of plants consist of cellulose.

Another important difference to plants is that fungi, as heterotrophic organisms, have no chlorophyll, do not carry out photosynthesis and must obtain their energy from organic substances of other organisms [39]. In addition, they do not perform active locomotion.

The nomenclature of fungi is binominal, i.e. each organism has a genus and a species name. However, changes in the names of fungi are relatively frequent due to new findings and taxonomic classifications. Until a few years ago, taxonomic classifications were mainly based on morphological characteristics. New taxonomic descriptions are based on a combination of morphology, physiology and genetic characteristics [20, 98, 99]. The use of molecular biological techniques to identify molds has provided new insights into the phylogeny of different mold species. It has been shown, for example, that many organisms that were previously grouped together as a single species, although morphologically and physiologically almost identical, are usually closely related but are genetically too different to belong to a single species. Currently, phylogenetically closely related species are regarded as species complexes.

For example, molecular biology has so far identified 15 species that were previously grouped morphologically under “*Aspergillus versicolor*”, an indicator organism for moisture damage. The species delimitation within this complex has not yet been conclusively clarified. The species of this complex isolated indoors were predominantly identified as *Aspergillus jensenii*, *A. versicolor*, *A. protuberus* or *A. creber*. For many complexes, identification of the molds down to the species level is only possible by molecular biology. For the general, hygienic assessment of mold fungi indoors using the Federal Environment Agency’s guideline “On the prevention, detection and remediation of mold infestation in buildings” [47], classification as belonging to the *A. versicolor* complex is sufficient. In test reports and expert opinions, the different species of the *Aspergillus versicolor* complex can therefore be summarized by stating the identification criteria used or the literature used [30].

Aspergilli with asexual and sexual stages previously had a separate name for each stage, for example *Eurotium* and *Aspergillus*. There are currently discussions about naming both stages after the asexual form, i.e. ***Aspergillus*** for the *Eurotium* and *Aspergillus* structures.

This can lead to communication problems if, for example, doctors list indoor mold species in their reports that are named differently according to the new nomenclature and include them in their assessment of possible health problems. In scientific articles and expert reports, the currently valid name for the designation of a mold should therefore be used wherever pos-

sible, for example the scientifically correct designation *Penicillium chrysogenum* instead of *Penicillium notatum*, a name still frequently used in the medical field.

In MycoBank, an online database, the current names and combinations as well as associated data, for example descriptions and illustrations, are accessible (<https://www.mycobank.org/>).

In medical mycology, however, fungi are classified clinically and independently of taxonomy into dermatophytes, yeasts, and molds. Although the DHS system (DHS, dermatophytes, yeasts, molds) is a practicable classification, this classification is misleading and incorrect from a biological (taxonomic) point of view because molds do not represent a taxonomic unit and most “yeasts” (shoot fungi), like dermatophytes, belong taxonomically to the *Ascomycota*.

Microbiologically, molds should generally be taxonomically indicated as genus and species. If only the Latin genus name and then sp. or spp. are given, the species or the individual species have not been further differentiated.

Mycotoxins

Mycotoxins are secondary metabolites of molds that can have toxic effects on various cell systems of vertebrates in low concentrations ($\mu\text{g}/\text{kg}$ food), depending on the type of toxin and consumption habits: Mycotoxins are to be distinguished from the fungal toxins of basidiomycetes (stator fungi). Numerous mold genera (including *Aspergillus*, *Penicillium*, *Fusarium*, *Alternaria*, *Stachybotrys*) can form mycotoxins. Mycotoxin formation depends on the species and on environmental factors such as substrate composition, humidity, pH value, light wavelength, and nutrient competition [27]. Mycotoxins are mostly low molecular weight compounds, many of which are formed in polyketide metabolism; the fungal toxins of basidiomycetes are usually oligopeptides.

In general, mycotoxins from indoor molds can be found in low concentrations (ppt) in house dust [11], in bioaerosols and on building materials. Mycotoxins can also occur in human blood [5]. However, the mycotoxins detected here (aflatoxins, ochratoxins, citrinin, patulin, various trichothecenes from *Fusarium* species) are only produced by food-relevant molds, but not by indoor-relevant species. The only exception is sterigmatocystin [5], which is formed as an intermediate product in the aflatoxin biosynthesis of “yellow” aspergilli (*A. flavus* group) and can also be formed as an end product by the *Aspergillus versicolor* complex and has been detected in house dust [21, 23]. Since the concentration of mycotoxins in food is 100 to 1000 times higher than in house dust and bioaerosols, it can be assumed that the mycotoxins in the human body were primarily absorbed via the food pathway. Against this background, it is much more likely that possible internal exposure to sterigmatocystin in humans is acquired via the food pathway than via the

inhalation pathway (indoor exposure). However, a differentiated human biomonitoring study on this is still lacking. Mycotoxins are not volatile, but occur in the air bound to spores, cell fragments and other particles.

As mycotoxins arise from secondary metabolism, they have no physiological significance in the metabolism of the fungus according to current knowledge. They are “waste products” that have only acquired an ecological significance in the course of evolution (e.g., the antibioticly or antimycotically active substances inhibit competitors in the biotope). Mycotoxins are generally only found in health-relevant concentrations in food and animal feed if these have been colonized by molds. A distinction must be made between so-called field pests (primarily *Fusarium* species), which produce mycotoxins on crops, and storage pests (*Aspergillus* and *Penicillium*), which synthesize mycotoxins under warm and humid conditions during storage.

As has been shown in cell culture and animal experiments, mycotoxins trigger cytotoxic effects [26, 102] and have immunomodulatory effects [75]. The cytotoxic effect of some mycotoxins on lung cells depends on their concentration. The data available to date allow the conclusion that the concentrations of most airborne mycotoxins to be expected indoors have no acute toxic effect. Only the most potent toxic compounds, such as the satratoxins (trichothecenes) of *Stachybotrys* species, could be present in indoor environments in their active concentrations due to mold-infested materials [25]. Individual studies indicate that the effective concentration of, for example, aflatoxin, which is detectable in house dust but is not produced by indoor-relevant fungal species, in cell systems from the lungs (pulmonary uptake, humans) is about an order of magnitude (factor 10) below the effective concentration in kidney cells (oral exposure, animals) [26].

However, the maximum expected concentrations of individual mycotoxins *in situ* (bioaerosols) cannot explain the cytotoxic effects alone. Rather, synergistic effects of different mycotoxins or of mycotoxins with other cell components (e.g., glucans, endotoxins) appear to be responsible for the effects [55].

Even taking into account the higher sensitivity of, for example, primary lung epithelial cells (factor 10 compared to immortalized cells, A 549), the expected exposure concentrations in the air are about a factor of 100 below the effect concentrations in the cell culture-based approach [27, 79]. The only exception here are the satratoxins (trichothecenes) of *Stachybotrys chartarum*, which could possibly be in the order of magnitude of the effect concentration under extreme exposure conditions (e.g., during indoor refurbishment). It cannot yet be ruled out that aerogenic concentrations reach a magnitude that could be responsible for immunomodulatory effects and thus possibly promote susceptibility to infection or allergy development or allergy intensification [87].

There is a particular need for research into the possible effects and synergies of various noxins, such as mycotoxins in combination with LPS (lipopolysaccharides of bacteria, endotoxins), with β -glucans (cell wall components of fungi) or other groups of organisms (e.g., actinobacteria) [86, 113].

Cell wall components, enzymes and other mold components and metabolic products

In addition to mold spores and mycotoxins, other mold components and metabolites, such as microbial volatile organic compounds (MVOCs), β -glucans, mannans and ergosterol, also play a role in exposures to molds [73, 74], whereby the MVOCs are responsible for the typical mold odor.

Ergosterol (ergosterol) is a metabolic product (sterol) of yeasts, molds, and edible fungi. It is formed in varying quantities as a membrane component, toxic properties are not known.

In connection with moisture damage, other microbiological components such as the lysosomal enzyme N-acetyl- β -D-glucosaminidase and lipopolysaccharides of gram-negative bacteria (LPS, endotoxin) are also increasingly present (e.g., in house dust) [72]. It is not clear whether these markers (cell fragments, β -glucan, ergosterol) correlate better with health effects than mold or spore concentrations [16, 28, 32, 41, 88, 91, 116].

To date, 77 proteins have been described and officially recognized as allergens of molds (excluding dermatophytes and yeasts) (www.allergen.org). The associated protein families differ significantly biochemically and structurally from the allergen families in pollen, food, or animal epithelia [50].

The most prominent representatives of mold allergens are [26, 50]:

- Proteases ($n=18$, 16 of which are serine proteases)
- Ribosomal proteins ($n=9$)
- Enolases ($n=5$)
- Dehydrogenases ($n=4$)
- Thioredoxins ($n=3$)
- Heat shock proteins (HSP 70/90) ($n=3$)
- Peroxisomal proteins ($n=2$)
- Isomerases ($n=2$)
- Superoxide dismutases MnSOD ($n=2$)
- Flavodoxins ($n=2$)

Other mold allergens can be found among the mitogilins, cyclophilins, fibrinogen-binding proteins and proteins with no known biochemical function [50].

A working group led by Olynych [83] demonstrated an immunomodulatory and proinflammatory effect of zymosan. They showed that zymosan leads to increased leukotriene production in mast cells via a dectin-dependent mechanism.

Mood disorders, unspecific symptoms

Disorders of well-being are defined as “deteriorations in psychological, physical and social well-being as well as the feeling of subjective performance. As an emotional experience, they are to be distinguished from annoyance reactions that involve a cognitive evaluation of specific environmental stimuli” [12, 14]. Disturbances of well-being play a significant role in environment-associated health disorders in general and in indoor-associated health disorders in particular [125]. The following three models are used to explain the mechanisms of action of such environment-associated mood disorders [12, 14]:

- a. Model of the noxe:
 - Physiological relationship between an environmental factor and a person’s reaction, for example to a psychotropic substance.
- b. Model of attribution:
 - A health condition is attributed to an environmental factor according to a cognitive assessment process.
- c. Stress model:
 - An environmental factor is consciously perceived and experienced as unpleasant, harmful, or threatening. Stress reactions can manifest themselves as physical dysfunctions, changes in well-being and impaired performance.

Changes in well-being can include anxiety, depression, impaired concentration and memory, psychophysiological activation reactions of blood pressure and hormone concentrations as well as vegetative complaints such as headaches and exhaustion.

The triggering of environment-associated mood disorders due to moisture damage and mold is possible in principle, for example through the visual, cognitive and/or odor-related perception of a possible mold infestation [125].

In principle, anyone can be affected by discomfort caused by damp/mold damage indoors. This is a nuisance, not a health hazard.

Predisposing factors for mood disorders can be environmental concerns, fears, conditioning, and attributions as well as a variety of illnesses [124].

Environmental medical syndromes

Syndromes are widespread in medicine. In addition to the syndrome, the disease also requires a clear and unambiguous determination of the cause [34, 63]. A syndrome (Greek: σύγδομος = convergence) is a specific constellation of symptoms (or abnormalities) of a clinical picture,

1. the cause(s) of which may be currently or generally unknown
2. which can have various causes

3. which cannot be differentiated from other symptom constellations or cannot be differentiated with certainty, or
4. which are rather rare [34, 63].

Environmental medical syndromes include above all sick building syndrome (SBS) and multiple chemical sensitivity (syndrome) (MCS) and sometimes also chronic fatigue syndrome (CFS) [126].

Sick building syndrome

In numerous publications, mainly epidemiological studies, a possible connection between moisture/mold exposure and SBS (used synonymously: Building Related (Health) Symptoms; not correctly used as a synonym by definition: Building Related Illness¹) is discussed [1–3, 6, 8, 17, 19, 22, 24, 29, 33, 35, 38, 40, 42, 48, 49, 51–54, 56, 58, 61, 62, 64–66, 69–71, 76, 77, 80–82, 84, 85, 89, 90, 92–97, 100, 101, 103, 105–108, 110, 111, 114, 115, 117, 119, 127], even with a pre-SBS [78].

However, a variety of physical, chemical, biological, psychosocial and personal factors are discussed as possible causes of SBS, without a clear etiology having been determined to date. It is therefore assumed to be a multifactorial process in which the simultaneous occurrence of various influences and thus variable combined effects leads to the development of the syndrome [9, 10].

Multiple Chemical Sensitivity (Syndrome) (MCS)/ Idiopathic Environmental Intolerance (IEI)

Some studies discuss a possible link between indoor damp/mold infestation and MCS [45, 46, 51, 59, 68, 81, 112, 118, 120, 122, 123, 128, 129]. Dampness and Mold Hypersensitivity Syndrome is also occasionally reported [120, 121] or Toxic Mold Syndrome [51, 60]; the latter not without contradiction [15].

However, MCS is an impressive example of the complex, often very individual and subjective interactions between body, psyche and environment [36, 37]. Despite the absence or low level of somatic findings, patients often suffer so much that it is almost impossible to cope with everyday life. This results in social and financial losses as well as high direct and indirect healthcare costs. The long-standing dualistic debate as to whether MCS is “physical” or “psychological” has unsettled many sufferers, wasted time and resources on searching for causes and attempting

¹ Definition of *Building Related Illness (BRI)*: Clinically clearly defined clinical pictures (including humidifier fever, legionellosis, indoor-associated allergies, e.g., to house dust mites or molds, indoor-associated malignancies such as radon-associated lung carcinoma) [67, 104], for which the etiology, pathology, pathophysiology, diagnosis, therapy, prevention and prognosis are clearly known.

treatment, but has not brought about any satisfactory improvement in the situation of MCS patients. They often feel turned away by “conventional medicine”, and doctor-patient relationships are regularly experienced as difficult. Those affected therefore often turn to alternative medical, scientifically unvalidated explanatory models and treatment methods, which may provide subjective relief, but rarely improve symptoms and participation and may be associated with dangerous side effects and high costs. From a scientific point of view, MCS is not yet a clearly definable clinical picture, but probably a special manifestation of a functional disease that is particularly stressful in individual cases [36, 37]. In particular, the lack of a causal relationship between exposure and symptoms, the chronic course and the comorbidities point to a general hypersensitivity that is not necessarily substance-related. However, their mechanisms of action, structural and functional correlates require further scientific substantiation, also with regard to their therapeutic modifiability. An understanding of MCS as a dysfunctional vicious circle of negative experiences and evaluations, psychophysiological tension and hyperreactivity offers both the patients themselves and their treating physicians a comprehensible psychoneurobehavioral model. It also implies at least potential reversibility and opens up concrete options for action, such as reviewing and relativizing threat expectations, focusing attention and avoidance behavior [36, 37].

Chronic fatigue syndrome

In contrast to the previously discussed syndromes, only a few studies address a possible link between indoor dampness/mold exposure and CFS [4, 31, 109].

Here, too, it must be taken into account that CFS is etiologically assumed to have a multifactorial genesis with biological, social and psychological factors [57]. In addition, the Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Board on the Health of Select Populations, Institute of Medicine has issued a 304-page statement on the subject of myalgic encephalomyelitis/chronic fatigue syndrome [18], in which terms such as mold, mycotoxins or MVOCs are not mentioned.

To date, there is insufficient evidence of an etiological link between the environmental medical syndromes SBS, MCS and CFS and indoor exposure to moisture/mold [43].

Conclusions

Based on the above, it can be concluded that neither the determination of MVOC and/or mycotoxins in indoor spaces nor human biomonitoring for mycotoxins is medically indicated due to suspected health problems or suspected SBS, MCS or CFS in connection with damp/mold damage in indoor spaces. Newly

coined terms, such as biotoxiosis and mold and vapor hypersensitivity syndrome (MDHS) or volatotoxins [7], suggest a nosological specificity of a pathophysiological connection for which, however, there is no evidence to date.

Funding Open Access funding enabled and organized by Projekt DEAL.

Conflict of interest J. Hurraß, R. Teubel, G. Fischer, B. Heinzow and G.A. Wiesmüller declare that they have no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. Ahearn DG, Crow SA, Simmons RB, Price DL, Noble JA, Mishra SK, et al. Fungal colonization of fiberglass insulation in the air distribution system of a multi-story office building: VOC production and possible relationship to a sick building syndrome. *J Ind Microbiol.* 1996;16:280–5.
2. Al-Ahmad M, Manno M, Ng V, Ribeiro M, Liss GM, Tarlo SM. Symptoms after mould exposure including *stachybotrys chartarum*, and comparison with darkroom disease. *Allergy.* 2010;65:245–55.
3. Ando M. Indoor air and human health—sick house syndrome and multiple chemical sensitivity. *Kokuritsu Iyakuhiin Shokuhin Eisei Kenkyusho Hokoku.* 2002;120:6–38. Article in Japanese.
4. Anyanwu E, Campbell AW, Jones J, Ehiri JE, Akpan AI. The neurological significance of abnormal natural killer cell activity in chronic toxigenic mold exposures. *Sci World J.* 2003;3:1128–37.
5. Arce-López B, Lizarraga E, Vettorazzi A, González-Peñas E. Human biomonitoring of mycotoxins in blood, plasma and serum in recent years: a review. *Toxins.* 2020;12:147.
6. Assoulin-Daya Y, Leong A, Shoenfeld Y, Gershwin ME. Studies of sick building syndrome. IV. Mycotoxicosis. *J Asthma.* 2002;39:191–201.
7. Bennett JW, Inamdar AA. Are some fungal volatile organic compounds (VOCs) mycotoxins? *Toxins.* 2015;7:3785–804.
8. Bholah R, Subratty AH. Indoor biological contaminants and symptoms of sick building syndrome in office buildings in Mauritius. *Int J Environ Health Res.* 2002;12:93–8.
9. Bischof W, Bullinger-Naber M, Kruppa B, Müller BH, Schwab R. Expositionen und gesundheitliche Beeinträchtigungen in Bürogebäuden. Stuttgart: Fraunhofer IRB Verlag; 2003.
10. Bischof W, Wiesmüller GA. Sick Building Syndrome (SBS). In: Albers K-J, editor. *Recknagel – Sprenger – Albers – Taschenbuch für Heizung + Klimatechnik.* 80th ed. Vol.

- 1, 2. München: DIV Deutscher Industrieverlag; 2022. pp. 108–18.
11. Bloom E, Grimsley LF, Pehrson C, Lewis J, Larsson L. Molds and mycotoxins in dust from water-damaged homes in new Orleans after hurricane Katrina. *Indoor Air*. 2009;19:153–8.
 12. Bullinger M. V-13 Befindlichkeitsstörungen. In: Wichmann H-E, Schlipkötter H-W, Füllgraf G, editors. *Handbuch der Umweltmedizin*. Landsberg/Lech: ecomed; 1992. pp. 1–12.
 13. Bullinger M. Erfassung des Befindens in Innenräumen. In: Verein Deutscher Ingenieure, Kommission Reinhaltung der Luft im VDI und DIN, editors. *Luftverunreinigung in Innenräumen*. VDI Berichte 1122. Düsseldorf: VDI; 1994. pp. 633–44.
 14. Bullinger M. 12.3 Befindlichkeitsstörungen. In: Dott W, Merk HF, Neuser J, Osieka R, editors. *Lehrbuch der Umweltmedizin*. Stuttgart: Wissenschaftliche Verlagsgesellschaft; 2002. pp. 494–500.
 15. Chapman JA, Terr AI, Jacobs RL, Charlesworth EN, Bardana EJ Jr. Toxic mold: phantom risk vs science. *Ann Allergy Asthma Immunol*. 2003;91:222–32.
 16. Choi H, Byrne S, Larsen LS, Sigsgaard T, Thorne PS, Larson L, et al. Residential culturable fungi, (1-3, 1-6)- β -D-glucan, and ergosterol concentrations in dust are not associated with asthma, rhinitis, or eczema diagnoses in children. *Indoor Air*. 2014;24:158–70.
 17. Christen K. Mold growth linked to airtight building designs. *Environ Sci Technol*. 2002;36:95A–6A.
 18. Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Board on the Health of Select Populations, Institute of Medicine. *Beyond myalgic encephalomyelitis/chronic fatigue syndrome: redefining an illness*. Washington (DC): National Academies Press (US); 2015.
 19. Cooley JD, Wong WC, Jumper CA, Straus DC. Correlation between the prevalence of certain fungi and sick building syndrome. *Occup Environ Med*. 1998;55:579–84.
 20. de Hoog GS, Guarro J, Gené J, Ahmed S, Al-Hatmi AMS, Figueras MJ, et al. *Atlas of clinical fungi*. 4th ed. Hilversum. 2020.
 21. Despot DJ, Kocsubé S, Bencsik O, Kecskeméti A, Szekeres A, Vagvölgi C, et al. Species diversity and cytotoxic potency of airborne sterigmatocystine-producing aspergilli from the section *versicolores*. *Sci Total Environ*. 2016;562:296–304.
 22. Ebbenhøj NE, Hansen MØ, Sigsgaard T, Larsen L. Building-related symptoms and molds: a two-step intervention study. *Indoor Air*. 2002;12:273–7.
 23. Engelhart S, Looock A, Skutlarek D, Sagunski H, Lommel A, Färber H, et al. Occurrence of toxigenic *Aspergillus versicolor* isolates and sterigmatocystin in carpet dust from damp indoor environments. *Appl Environ Microbiol*. 2002;68:3886–90.
 24. Engvall K, Norrby C, Norbäck D. Ocular, airway, and dermal symptoms related to building dampness and odors in dwellings. *Arch Environ Health*. 2002;57:304–10.
 25. Fischer G, Thißen R, Müller T, Braun S, Dott W. Mikrobielle Stoffwechselprodukte als Meßparameter bei Emissionsbeurteilungen an Bioabfall-Behandlungsanlagen. *Gefahrst Reinhalt Luft*. 2004;64:229–38.
 26. Fischer G, Thißen R, Hinz R-K, Hollbach N, Schmitz C, Dott W. Luftgetragene Schimmelpilze in der Umwelt des Menschen – gesundheitliche Relevanz und Möglichkeiten der Risikobewertung. *Gefahrst Reinhalt Luft*. 2005;65:335–40.
 27. Fischer G, Thißen R, Schmitz C, Dott W. Relevance of microfungi and their secondary metabolites (mycotoxins) for indoor hygiene. *Proc Healthy Build*. 2006;1:189–94.
 28. Frankel M, Hansen EW, Madsen AM. Effect of relative humidity on the aerosolization and total inflammatory potential of fungal particles from dust-inoculated gypsum boards. *Indoor Air*. 2014;24:16–28.
 29. Fu X, Norbäck D, Yuan Q, Li Y, Zhu X, Hashim JH, et al. Association between indoor microbiome exposure and sick building syndrome (SBS) in junior high schools of Johor Bahru, Malaysia. *Sci Total Environ*. 2021;753:141904.
 30. Gabrio T. Woran erkenne ich ein qualifiziertes Schimmelpilzlabor? *Bausachverständige*. 2020;16:33–9.
 31. Gharibzadeh S, Hoseini SS. Is there any relation between moldy building exposure and chronic fatigue syndrome? *Med Hypotheses*. 2006;66:1243–4.
 32. Górny RL, Reponen T, Willeke K, Schmechel D, Robine E, Boissier M, et al. Fungal fragments as indoor air biocontaminants. *Appl Environ Microbiol*. 2002;68:3522–31.
 33. Gottschalk C, Bauer J, Meyer K. Detection of satratoxin G and H in indoor air from a water-damaged building. *Mycopathologia*. 2008;166:103–7.
 34. Gross R, Löffler M. *Prinzipien der Medizin. Eine Übersicht ihrer Grundlagen und Methoden*. Berlin, Heidelberg, New York: Springer; 1997.
 35. Harrison J, Pickering CA, Faragher EB, Austwick PK, Little SA, Lawton L. An investigation of the relationship between microbial and particulate indoor air pollution and the sick building syndrome. *Respir Med*. 1992;86:225–35.
 36. Hausteiner-Wiehle C, Bornschein S, Hornberg C, Wiesmüller GA. Multiple Chemical Sensitivity (MCS) / Idiopathic Environmental Intolerances (IEI). In: Wichmann HE, Fromme H, editors. *Handbuch der Umweltmedizin*, 68. Erg.-Lfg. 12/2020. Landsberg/Lech: ecomed; 2020. pp. 1–30. Kap. V-13.3.
 37. Hausteiner-Wiehler C, Bornschein S, Hornberg C, Wiesmüller GA. Multiple Chemical Sensitivity (MCS) / Idiopathic Environmental Intolerances (IEI). In: Letzel S, Nowak D, editors. *Handbuch der Arbeitsmedizin*, 58. Erg.-Lfg. 12/2020. Landsberg/Lech: ecomed; 2020. pp. 1–30. Kap. DI-13.1.2.
 38. Hiipakka DW, Buffington JR. Resolution of sick building syndrome in a high-security facility. *Appl Occup Environ Hyg*. 2000;15:635–43.
 39. Hinke M, Seibert M. *Pilze in Innenräumen und am Arbeitsplatz*. Wien: Springer; 2013.
 40. Hintikka EL. The role of stachybotrys in the phenomenon known as sick building syndrome. *Adv Appl Microbiol*. 2004;55:155–73.
 41. Hirvonen M-R, Huttunen K, Roponen M. Bacterial strains from moldy buildings are highly potent inducers of inflammatory and cytotoxic effects. *Indoor Air*. 2005;15(Suppl 9):65–70.
 42. Hossain MA, Ahmed MS, Ghannoum MA. Attributes of stachybotrys chartarum and its association with human disease. *J Allergy Clin Immunol*. 2004;113:200–8.
 43. Hurraß J, Fischer G, Herr CEW, Wiesmüller GA. *Mykotoxine: Thesen. Tagungsband zum 11. Fachkongress der Arbeitsgemeinschaft ökologischer Forschungsinstitute (AGÖF)*. Springe-Eldagsen: Eigenverlag 2016, 138–154. Stellungnahme zum Beitrag von Carmen Kroccek, Jochen Kern und Hartmut M. Hanauke-Abel. *Umweltmed Hyg Arbeitsmed*. 2017;22:1–10.
 44. Hurraß J, Heinzow B, Walser-Reichenbach S, Aurbach U, Becker S, Bellmann R, et al. AWMF-Schimmelpilz-Leitlinie „Medizinisch klinische Diagnostik bei Schimmelpilzexposition in Innenräumen – update 2023“. AWMF-register-Nr. 161/001. <http://www.awmf.org/leitlinien/detail/ll/161-001.html>.
 45. Hyvönen S, Lohi J, Tuuminen T. Moist and mold exposure is associated with high prevalence of neurological symptoms

- and MCS in a finnish hospital workers cohort. *Saf Health Work*. 2020;11:173–7.
46. Hyvönen S, Poussa T, Lohi J, Tuuminen T. High prevalence of neurological sequelae and multiple chemical sensitivity among occupants of a finnish police station damaged by dampness microbiota. *Arch Environ Occup Health*. 2021;76:145–51.
 47. Innenraumlufthygiene-Kommission des Umweltbundesamtes. Leitfaden zur Vorbeugung, Erfassung und Sanierung von Schimmelbefall in Gebäuden. Dessau-Roßlau: Umweltbundesamt; 2017.
 48. Johanning E. Indoor moisture and mold-related health problems. *Eur Ann Allergy Clin Immunol*. 2004;36:182–5.
 49. Kanazawa A, Saijo Y, Tanaka M, Yoshimura T, Chikara H, Takigawa T, et al. Nationwide study of sick house syndrome: comparison of indoor environment of newly built dwellings between Sapporo city and southern areas including those in Honshu and Kyushu. *Nihon Eiseigaku Zasshi*. 2010;65:447–58.
 50. Kespohl S, Raulf M. Mould allergens: how far has molecular allergy diagnosis come? Part 13 of the series molecular allergology. *Allergo J Int*. 2014;23:120–5.
 51. Khalili B, Montanaro MT, Bardana EJ Jr. Inhalational mold toxicity: fact or fiction? A clinical review of 50 cases. *Ann Allergy Asthma Immunol*. 2005;95:239–46.
 52. Kielb C, Lin S, Muscatiello N, Hord W, Rogers-Harrington J, Healy J. Building-related health symptoms and classroom indoor air quality: a survey of school teachers in New York state. *Indoor Air*. 2015;25:371–80.
 53. Kilburn KH. Role of molds and mycotoxins in being sick in buildings: neurobehavioral and pulmonary impairment. *Adv Appl Microbiol*. 2004;55:339–59.
 54. Kishi R, Saijo Y, Kanazawa A, Tanaka M, Yoshimura T, Chikara H, et al. Regional differences in residential environments and the association of dwellings and residential factors with the sick house syndrome: a nationwide cross-sectional questionnaire study in Japan. *Indoor Air*. 2009;19:243–54.
 55. Kommission „Methoden und Qualitätssicherung in der Umweltmedizin“ des Robert Koch-Instituts. Schimmelpilzbelastung in Innenräumen – Befunderhebung, gesundheitliche Bewertung und Maßnahmen. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz*. 2007;50:1308–23.
 56. Kramer A, Wichelhaus TA, Kempf V, Hogardt M, Zacharowski K. Building-related illness (BRI) in all family members caused by mold infestation after dampness damage of the building. *GMS Hyg Infect Control*. 2021;16:Doc32.
 57. Lahmann C, Dinkel A. Chronisches Erschöpfungssyndrom (CFS). In: Letzel S, Nowak D, editors. *Handbuch der Arbeitsmedizin*. 26. Erg. Lfg. 9/12. Landsberg/Lech: ecomed; 2012. pp. 1–20.
 58. Laumbach RJ, Kipen HM. Bioaerosols and sick building syndrome: particles, inflammation, and allergy. *Curr Opin Allergy Clin Immunol*. 2005;5:135–9.
 59. Lee TG. Health symptoms caused by molds in a courthouse. *Arch Environ Health*. 2003;58:442–6.
 60. Levy MB, Fink JN. Toxic mold syndrome. *Adv Appl Microbiol*. 2004;55:275–88.
 61. Li CS, Hsu CW, Tai ML. Indoor pollution and sick building syndrome symptoms among workers in day-care centers. *Arch Environ Health*. 1997;52:200–7.
 62. Linz DH, Pinney SM, Keller JD, White M, Buncher CR. Cluster analysis applied to building-related illness. *J Occup Environ Med*. 1998;40:165–71.
 63. Lipkin M. Functional or organic? A pointless question. *Ann Intern Med*. 1969;71:1013–7.
 64. Lu C, Deng Q, Li Y, Sundell J, Norbäck D. Outdoor air pollution, meteorological conditions and indoor factors in dwellings in relation to sick building syndrome (SBS) among adults in China. *Sci Total Environ*. 2016;560–561:186–96.
 65. Lukso D, Guidotti TL, Franklin DE, Burt A. Indoor environmental and air quality characteristics, building-related health symptoms, and worker productivity in a federal government building complex. *Arch Environ Occup Health*. 2016;71:85–101.
 66. Mahmoudi M, Gershwin ME. Sick building syndrome. III. *Stachybotrys chartarum*. *J Asthma*. 2000;37:191–8.
 67. Maroni M, Levy F. Definitions. In: Levy F, Maroni M, editors. *NATO/ CCMS pilot study on indoor air quality. 4th plenary meeting. Epidemiology and medical management of building-related complaints and illnesses*. Oslo: National Institute of Occupational Health; 1992. pp. 160–1.
 68. Masri S, Miller CS, Palmer RF, Ashford N. Toxicant-induced loss of tolerance for chemicals, foods, and drugs: assessing patterns of exposure behind a global phenomenon. *Environ Sci Eur*. 2021;33:65.
 69. McGrath JJ, Wong WC, Cooley JD, Straus DC. Continually measured fungal profiles in sick building syndrome. *Curr Microbiol*. 1999;38:33–6.
 70. Meyer HW, Würtz H, Suadicani P, Valbjørn O, Sigsgaard T, Gyntelberg F, Working Group under the Danish Mould in Buildings program (DAMIB). Molds in floor dust and building-related symptoms in adolescent school children. *Indoor Air*. 2004;14:65–72.
 71. Meyer HW, Würtz H, Suadicani P, Valbjørn O, Sigsgaard T, Gyntelberg F, Working Group under the Danish Mold in Buildings program (DAMIB). Molds in floor dust and building-related symptoms among adolescent school children: a problem for boys only? *Indoor Air*. 2005;15(Suppl 10):17–24.
 72. Mücke W, Lemmen C. Bioaerosole und Gesundheit: Wirkungen biologischer Luftinhaltsstoffe und praktische Konsequenzen. Landsberg/Lech: ecomed; 2008.
 73. Mücke W, Lemmen C. Bioaerosole – Risiken durch biologische Luftinhaltsstoffe Teil 1. *Umweltmed Forsch Prax*. 2011;16:383–91.
 74. Mücke W, Lemmen C. Bioaerosole – Risiken durch biologische Luftinhaltsstoffe Teil 2. *Umweltmed Forsch Prax*. 2012;17:35–45.
 75. Müller A, Lehmann I, Seiffart A, Diez U, Wetzig H, Borte M, et al. Increased incidence of allergic sensitisation and respiratory diseases due to mould exposure: results of the leipzig allergy risk children study (LARS). *Int J Hyg Environ Health*. 2002;204:363–5.
 76. Nakayama K, Morimoto K. Relationship between, lifestyle, mold and sick building syndromes in newly built dwellings in Japan. *Int J Immunopathol Pharmacol*. 2007;20:35–43.
 77. Nakayama K, Morimoto K. Risk factor for lifestyle and way of living for symptoms of epidemiological survey in Japan. *Nihon Eiseigaku Zasshi*. 2009;64:689–98. Article in Japanese.
 78. Nakayama Y, Nakaoka H, Suzuki N, Tsumura K, Hanazato M, Todaka E, et al. Prevalence and risk factors of pre-sick building syndrome: characteristics of indoor environmental and individual factors. *Environ Health Prev Med*. 2019;24:77.
 79. Nevalainen A, Täubel M, Hyvärinen A. Indoor fungi: companions and contaminants. *Indoor Air*. 2015;25:125–56.
 80. Niedoszytko M, Chelmińska M, Chelmiński K. Fungal allergy. Part I. *Pol Merkur Lekarski*. 2002;12:241–4. Article in Polish.
 81. Nordin S. Mechanisms underlying nontoxic indoor air health problems: A review. *Int J Hyg Environ Health*. 2020;226:113489.

82. Ochmański W, Barabasz W. Microbiological threat from buildings and rooms and its influence on human health (sick building syndrome). *Przegl Lek.* 2000;57:419–23. Article in Polish.
83. Olynych TJ, Jakeman DL, Marshall JS. Fungal zymosan induces leukotriene production by human mast cells through a dectin-1-dependent mechanism. *J Allergy Clin Immunol.* 2006;118:837–43.
84. Page EH, Trout DB. The role of stachybotrys mycotoxins in building-related illness. *AIHAJ.* 2001;62:644–8.
85. Park JH, Cox-Ganser J, Rao C, Kreiss K. Fungal and endotoxin measurements in dust associated with respiratory symptoms in a water-damaged office building. *Indoor Air.* 2006;16:192–203.
86. Peitzsch M, Sulyok M, Täubel M, Vishwanath V, Krop E, Borràs-Santos A, et al. Microbial secondary metabolites in school buildings inspected for moisture damage in Finland, the Netherlands and Spain. *J Environ Monit.* 2012;14:2044–53.
87. Pestka JJ, Yike I, Dearborn DG, Ward MDW, Harkema JR. Stachybotrys chartarum, trichothecene mycotoxins, and damp building-related illness: new insights into a public health enigma. *Toxicol Sci.* 2008;104:4–26.
88. Rao CY, Cox-Ganser JM, Chew GL, Doekes G, White S. Use of surrogate markers of biological agents in air and settled dust samples to evaluate a water-damaged hospital. *Indoor Air.* 2005;15(Suppl 9):89–97.
89. Rea WJ, Didriksen N, Simon TR, Pan Y, Fenyves EJ, Griffiths B. Effects of toxic exposure to molds and mycotoxins in building-related illnesses. *Arch Environ Health.* 2003;58:399–405.
90. Reijula K. Moisture-problem buildings with molds causing work-related diseases. *Adv Appl Microbiol.* 2004;55:175–89.
91. Rylander R. Airborne (1-->3)-beta-D-Glucan and airway disease in a day-care center before and after renovation. *Arch Environ Health.* 1997;52:281–5.
92. Rylander R. Microbial cell wall agents and sick building syndrome. *Adv Appl Microbiol.* 2004;55:139–54.
93. Sahlberg B, Mi YH, Norbäck D. Indoor environment in dwellings, asthma, allergies, and sick building syndrome in the Swedish population: a longitudinal cohort study from 1989 to 1997. *Int Arch Occup Environ Health.* 2009;82:1211–8.
94. Sahlberg B, Wieslander G, Norbäck D. Sick building syndrome in relation to domestic exposure in Sweden—a cohort study from 1991 to 2001. *Scand J Public Health.* 2010;38:232–8.
95. Sahlberg B, Norbäck D, Wieslander G, Gislason T, Janson C. Onset of mucosal, dermal, and general symptoms in relation to biomarkers and exposures in the dwelling: a cohort study from 1992 to 2002. *Indoor Air.* 2012;22:331–8.
96. Sahlberg B, Gunnbjörnsdóttir M, Soon A, Jogi R, Gislason T, Wieslander G, et al. Airborne molds and bacteria, microbial volatile organic compounds (MVOC), plasticizers and formaldehyde in dwellings in three north European cities in relation to sick building syndrome (SBS). *Sci Total Environ.* 2013;444:433–40.
97. Saijo Y, Yoshida T, Kishi R. Dampness, biological factors and sick house syndrome. *Nihon Eiseigaku Zasshi.* 2009;64:665–71. Article in Japanese.
98. Samson RA. Rückblick und Ausblick – Taxonomie und Bestimmung der Schimmelpilze im Wandel. In: Berufsverband Deutscher Baubiologen VDB e.V., editor. Tagungsband der 21. Pilztagung AnBUS; Fürth. 2017. pp. 27–36.
99. Samson RA, Houbraken J, Thrane U, Frisvad JC, Andersen B. Food and indoor fungi. *Westerdijk laboratory manual series.* 2nd ed. Westerdijk Laboratory Manual series. Utrecht: Westerdijk Fungal Biodiversity Institute; 2019.
100. Sayan HE, Dülger S. Evaluation of the relationship between sick building syndrome complaints among hospital employees and indoor environmental quality. *Med Lav.* 2021;112:153–61.
101. Scheel CM, Rosing WC, Farone AL. Possible sources of sick building syndrome in a tennessee middle school. *Arch Environ Health.* 2001;56:413–7.
102. Schulz T, Senkpiel K, Ohgke H. Comparison of the toxicity of reference mycotoxins and spore extracts of common indoor moulds. *Int J Hyg Environ Health.* 2004;207:267–77.
103. Schwab CJ, Straus DC. The roles of penicillium and Aspergillus in sick building syndrome. *Adv Appl Microbiol.* 2004;55:215–38.
104. Seifert B. Das „sick building“-Syndrom. *Öff Gesundheitswes.* 1991;53:376–82.
105. Seki A, Takigawa T, Kishi R, Sakabe K, Torii S, Tanaka M, et al. Review of sick house syndrome. *Nihon Eiseigaku Zasshi.* 2007;62:939–48. Article in Japanese.
106. Shoemaker RC, House DE. A time-series study of sick building syndrome: chronic, biotoxin-associated illness from exposure to water-damaged buildings. *Neurotoxicol Teratol.* 2005;27:29–46.
107. Shoemaker RC, House DE. Sick building syndrome (SBS) and exposure to water-damaged buildings: time series study, clinical trial and mechanisms. *Neurotoxicol Teratol.* 2006;28:573–88.
108. Smedje G, Wang J, Norbäck D, Nilsson H, Engvall K. SBS symptoms in relation to dampness and ventilation in inspected single-family houses in Sweden. *Int Arch Occup Environ Health.* 2017;90:703–11.
109. Somppi TL. Non-thyroidal illness syndrome in patients exposed to indoor air dampness microbiota treated successfully with triiodothyronine. *Front Immunol.* 2017;8:919.
110. Straus DC, Cooley JD, Wong WC, Jumper CA. Studies on the role of fungi in sick building syndrome. *Arch Environ Health.* 2003;58:475–8.
111. Straus DC. The possible role of fungal contamination in sick building syndrome. *Front Biosci.* 2011;3:562–80.
112. Suojalehto H, Ndika J, Lindström I, Airaksinen L, Karvala K, Kauppi P, et al. Transcriptomic profiling of adult-onset asthma related to damp and moldy buildings and idiopathic environmental intolerance. *Int J Mol Sci.* 2021;22:10679.
113. Täubel M, Sulyok M, Vishwanath V, Bloom E, Turunen M, Järvi K, et al. Co-occurrence of toxic bacterial and fungal secondary metabolites in moisture-damaged indoor environments. *Indoor Air.* 2011;21:368–75.
114. Takeda M, Saijo Y, Yuasa M, Kanazawa A, Araki A, Kishi R. Relationship between sick building syndrome and indoor environmental factors in newly built Japanese dwellings. *Int Arch Occup Environ Health.* 2009;82:583–93.
115. Terr AI. Sick building syndrome: is mould the cause? *Med Mycol.* 2009;47(Suppl 1):S217–S22.
116. Tischer CG, Heinrich J. Exposure assessment of residential mould, fungi and microbial components in relation to children's health: achievements and challenges. *Int J Hyg Environ Health.* 2013;216:109–14.
117. Tsai YJ, Gershwin ME. The sick building syndrome: what is it when it is? *Compr Ther.* 2002;28:140–4.
118. Tuuminen T, Rinne KS. Severe sequelae to mold-related illness as demonstrated in two finnish cohorts. *Front Immunol.* 2017;8:382.
119. Tuuminen T. The roles of autoimmunity and biotoxigenesis in sick building syndrome as a “starting point” for irreversible dampness and mold hypersensitivity syndrome. *Antibodies.* 2020;9:26.

120. Tuuminen T. Dampness and mold hypersensitivity syndrome, or mold-related illness, has become highly politicized and downplayed in Finland. *Altern Ther Health Med.* 2021;27:59–64.
121. Valtonen V. Clinical diagnosis of the dampness and mold hypersensitivity syndrome: review of the literature and suggested diagnostic criteria. *Front Immunol.* 2017;8:951.
122. Vuokko A, Karvala K, Lampi J, Keski-Nisula L, Pasanen M, Voutilainen R, et al. Environmental intolerance, symptoms and disability among fertile-aged women. *Int J Environ Res Public Health.* 2018;15:293.
123. Vuokko A, Karvala K, Suojalehto H, Lindholm H, Selinheimo S, Heinonen-Guzejev M, et al. Clinical characteristics of disability in patients with indoor air-related environmental intolerance. *Saf Health Work.* 2019;10:362–9.
124. Wiesmüller GA, Szewzyk R, Baschien C, Gabrio T, Fischer G, Grün L, et al. Häufige Fragestellungen in Zusammenhang mit der Bewertung eines möglichen Geruchswirkungen und Befindlichkeitsstörungen Schimmelpilz-expositionen: Antworten eines round table auf dem workshop „Schimmelpilze – Geruchswirkungen und Befindlichkeitsstörungen“ im Rahmen der GHUP-Jahrestagung 2012. *Umweltmed Hyg Arbeitsmed.* 2013;18:35–40.
125. Wiesmüller GA, Heinzow B, Herr CEW. Befindlichkeitsstörungen in Innenräumen. In: Wiesmüller GA, Heinzow B, Herr CEW, editors. *Gesundheitsrisiko Schimmelpilze im Innenraum.* Heidelberg, München, Landsberg, Frechen, Hamburg: ecomed Medizin; 2013. pp. 313–20.
126. Wiesmüller GA, Hornberg C. Umweltmedizinische syndrome. *Bundesgesundheitsbl.* 2017;60:597–604.
127. Wilson SC, Carriker CG, Brasel TL, Karunasena E, Douglas DR, Wu C, et al. Culturability and toxicity of sick building syndrome-related fungi over time. *J Occup Environ Hyg.* 2004;1:500–4.
128. Yang Q, Wang J, Norbäck D. The home environment in a nationwide sample of multi-family buildings in Sweden: associations with ocular, nasal, throat and dermal symptoms, headache, and fatigue among adults. *Indoor Air.* 2021;31:1402–16.
129. Zhang X, Sahlberg B, Wieslander G, Janson C, Gislason T, Norbäck D. Dampness and moulds in workplace buildings: associations with incidence and remission of sick building syndrome (SBS) and biomarkers of inflammation in a 10 year follow-up study. *Sci Total Environ.* 2012;430:75–81.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.